ArticleCureus2026
Minimal Detectable Change and Minimal Clinically Important Difference of Bruininks-Oseretsky Test of Motor Proficiency Second Edition Balance Component in Patients With Cerebral Palsy: A Pilot Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Balance deficits are among the most disabling features of spastic cerebral palsy (CP), limiting mobility and participation. The balance subtest of the Bruininks-Oseretsky Test of Motor Proficiency Second Edition (BOT-2) in paediatric physiotherapy is widely used; however, its minimal clinically important difference (MCID) and minimal detectable change (MDC) for spastic CP children have not been reported. Hence, in spastic CP children, the current study primarily aimed to determine the MCID and MDC for the balance subtest of the BOT-2 and, as a secondary objective, to examine its concurrent validity with the Pediatric Balance Scale (PBS). Methods A total of 30 spastic CP children (Gross Motor Function Classification System (GMFCS) Levels I-II; mean age 8.35 ± 1.93 years) were assessed using the PBS and balance subtest of BOT-2 by two independent physiotherapists at baseline and after four weeks of conventional physiotherapy. The MDC and MCID were estimated with the PBS as the external anchor. Paired t-tests and Pearson correlation coefficients were applied for inferential analysis. Results Statistically significant improvements were observed in BOT-2 Balance and PBS scores for both assessors (p < 0.001). The MDC ranged from 1.5 to 1.7 points. Moderate-to-strong correlations were identified between BOT-2 and PBS change scores (r = 0.583-0.604, p ≤0.001). An MCID of ≥3.5 points across both assessors was consistently identified, with good-to-excellent discriminative capacity (AUC = 0.814-0.884). Conclusion The BOT-2 Balance subtest demonstrates good responsiveness in children with spastic CP. These preliminary findings provide an MDC of 1.5-1.7 points and an MCID of ≥3.5 points, providing evidence-based benchmarks for interpreting clinically meaningful balance improvement, supporting the integration of BOT-2 Balance into routine paediatric physiotherapy assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.